---
title: 'Empagliflozin in acute myocardial infarction in patients with and without
  type 2 diabetes: A pre-specified analysis of the EMPACT-MI trial'
date: '2024-12-26'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39725521/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241227170555&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSION: Patients with acute MI, LVEF <45% and/or congestion who
  had T2DM were at a higher risk of mortality than those without T2DM. Empagliflozin
  reduced first and total HF hospitalizations regardless of the presence or absence
  of ...'
disable_comments: true
---
CONCLUSION: Patients with acute MI, LVEF <45% and/or congestion who had T2DM were at a higher risk of mortality than those without T2DM. Empagliflozin reduced first and total HF hospitalizations regardless of the presence or absence of ...